We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




RF Ablation Effective in Treating Lung Cancer

By HospiMedica staff writers
Posted on 23 Dec 2002
The results of a clinical study have confirmed that radiofrequency (RF) ablation appears to be effective in treating cancerous lung tumors in patients who are not surgical candidates.

The study involved 62 patients with primary lung cancer or lung metastases who were not surgical candidates. More...
The patients were treated with the RF ablation system of Rita Medical Systems, Inc. (Mountain View, CA, USA). This system allows doctors to deliver monitored and controlled levels of RF energy into the cancerous tissue through an array of thin electrodes, which heat and destroy the targeted tissue. In many cases, this minimally invasive procedure can be performed using only a local anesthetic and intravenous sedation.

Following treatment, the patients' progress was assessed over a one-year period using computed tomography (CT) imaging. For 25 patients in the study who were followed for at least six months, 93% of tumors had stabilized or decreased in size. Over this period, these tumors would typically be expected to at least double in size, says Rita Medical. No major complications were reported.

"These results are very impressive. The data presented here clearly show that Rita can offer a new approach in the treatment of lung cancer for the majority of patients who cannot have surgery,” said Riccardo Lencioni, M.D., professor of diagnostic and interventional radiology at the University of Pisa (Italy), who presented the study results at the annual meeting of the Radiological Society of North America (RSNA) in Chicago, IL (USA).




Related Links:
Rita Medical

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.